CASE REPORT

Chromosomal coharboring of $bla_{IMP-60}$ and $mcr-9$ in Enterobacter asburiae isolated from a Japanese woman with empyema: a case report

Yusuke Miyazato¹*, Noriko Iwamoto¹*, Masaru Usui², Toyotaka Sato³,⁴, Tohru Miyoshi-Akiyama⁵, Maki Nagashima¹, Kazuhsa Mezaki⁶, Kayoko Hayakawa¹ and Norio Ohmagari¹

Abstract

Background: Polymyxin E (colistin) is a last-resort antibiotic to treat infections caused by carbapenemase-producing Enterobacteriaceae (CPE). However, reports of CPEs resistant to colistin have been increasing, and the mcr genes are emerging as resistance mechanisms. Among them, plasmid-mediated mcr-9 is known to be associated with colistin resistance, whereas reports on chromosomal mcr-9 and its association with colistin resistance in humans are few.

Case presentation: We identified Enterobacter asburiae harboring mcr-9 and $bla_{IMP-60}$ in the pleural fluid of a patient with empyema. The long-read sequencing technique revealed that these genes were located on its chromosome. Despite the lack of exposure to colistin, the organism showed microcolonies in the inhibition circle in the E-test and disk diffusion test. Antibiotic susceptibility testing by broth microdilution confirmed its resistance to colistin.

Conclusion: Our case report showed that mcr-9 can be present not only on plasmids but also on the chromosome in E. asburiae, and that the presence of mcr-9 on its chromosome may influence its susceptibility to colistin.

Keywords: mcr-9, BlaIMP, Chromosome, Heteroresistance, Case report

Background

Carbapenemase-producing Enterobacteriaceae (CPE) are a threat for healthcare providers because they can be resistant to many antimicrobial agents including carbapenems, and there are few reliable antimicrobial treatment options [1]. Reports of colistin-resistant CPE have improved our understanding of the mechanisms of resistance, including the acquisition of mobile colistin-resistance (mcr) genes (mcr-1 to mcr-10) [2–4]. The mcr genes, especially mcr-9, are frequently found in Enterobacter cloacae complex strains, and several of these strains co-harbor metallo-beta-lactamase genes, such as $bla_{NDM-1}$ and $bla_{KPC-2}$ [5]. Plasmid-borne mcr genes conferring resistance to colistin pose a serious threat to international public health [3]; in particular, IncHI2 plasmids bearing mcr-9 play a central role in the global spread of resistant strains [6]. While many reports of plasmid-borne mcr are available, there are only a few case reports on the detailed clinical course of infection and antibiotic susceptibility testing of Enterobacteriaceae carrying mcr and metallo-beta-lactamase genes on their chromosomes. Here, we report the case of a patient with empyema who carried E. asburiae harboring $bla_{IMP-60}$ and mcr-9 on its chromosome.
Case presentation
The patient was a 68-year-old previously healthy woman who had suffered from a severe sore throat for a week and was admitted after being diagnosed with septic shock, acute epiglottitis, descending mediastinitis, and bilateral pleural empyema due to *Streptococcus constellatus* and *Bacteroides thetaiotaomicron*. Although the patient received an intensive care with treatment by percutaneous drainage and intravenous piperacillin/tazobactam, she experienced a relapse of empyema due to *Enterobacter asburiae* resistant to meropenem and colistin (Table 1). Multiple resistant microcolonies were present within the zone of clearing by the E-test and disc diffusion method (Additional file 1 and 2: Fig. S1, S2). We suspected the strain was heteroresistant to colistin at first, but antibiotic susceptibility testing using broth microdilution (BMD) confirmed colistin resistance (Table 2).

A detailed next-generation sequencing study was carried out to examine the mechanism of drug resistance to colistin in the *E. asburiae* strain. The long-read sequencing technique revealed that in this case, *E. asburiae* co-harbored *mcr-9* and *bla*IMPL-60 on its chromosome (Fig. 1). By applying error correction twice using Pilon on short reads, an improvement in the overall sequence and length was achieved. Specifically, we performed the following analyses: (a) long-read sequencing reads were demultiplexed by Porechop v0.2.4 ([https://github.com/rrwick/Porechop](https://github.com/rrwick/Porechop)), and the reads were adaptor-trimmed and quality-filtered by Nanofilt (Q score, 9; minimum length, 1000 bp), (b) chimeric reads were removed using yacrd v0.6.0 ([https://github.com/natir/yacrd](https://github.com/natir/yacrd)), (c) the reads of errors were corrected by short-read sequencing reads with LoRDEC v0.8 software [7] with default parameters, (d) de novo assembly was performed by Flye v2.6 [8] (with default parameters using corrected long-read sequencing reads), (e) assembled contigs of errors were corrected by short-read sequencing reads with Pilon v1.23 [9] twice with default parameters, (f) genome and plasmid sequences were annotated using DFAST ([https://dfast.nig.ac.jp](https://dfast.nig.ac.jp)), and (g) antimicrobial resistance genes were detected using ResFinder v4.1 with default parameters on the CGE server ([http://www.genomicepidemiology.org](http://www.genomicepidemiology.org)). Subsequent long-read sequence analysis of *E. asburiae* using MinION revealed a circular chromosome (accession no. AP024281), which contained *bla*IMP60 and *mcr-9*. There were also resistance genes on the chromosome, such as *aac(6’)-Ile*, *bla*ACT-6, and *sul1_2*. *E. asburiae*, in this case, had only one plasmid (AP024282), but there were no resistance genes on it. A linear comparison of the *mcr-9*-surrounding regions of the chromosome of *E. asburiae* (AP024281) and a plasmid of *Salmonella* Infantis pRH-R27 was performed by BLAST and visualized using Easyfig v2.2.2 ([https://mjsull.github.io/Easyfig/](https://mjsull.github.io/Easyfig/)) (LN555650) (Fig. 1). The core structure of the reported *mcr-9* cassette, *renR-rena-pcoE-IS903-mcr-9-wbuc* [6], was also observed in the chromosome of *E. asburiae*.

The patient underwent repeated percutaneous drainage and intravenous antimicrobial therapy with piperacillin/tazobactam, gentamicin and levofloxacin for two months, then we switched oral therapy with trimethoprim/sulfamethoxazole and levofloxacin until resolution of the empyema in imaging studies. After being discharged on day 168, she is now living on her own after the rehabilitation therapy and has had no recurrences.

### Table 1

| Antibiotics                        | MIC (µg/ml) |
|------------------------------------|-------------|
| Ampicillin                         | ≥ 32        |
| Ampicillin/sulbactam               | ≥ 32        |
| Piperacillin/tazobactam            | ≥ 256       |
| Cefazolin                          | ≥ 32        |
| Cefpodoxime proxetil               | ≥ 16        |
| Cefmetazole                        | ≥ 64        |
| Ceftriaxone                        | ≥ 16        |
| Cefazidime                         | ≥ 32        |
| Cefepime                           | ≥ 32        |
| Latamoxef                          | ≥ 16        |
| Cefpodoxime/clavulanate            | ≥ 4         |
| Aztreonam                          | ≥ 16        |
| Meropenem                          | 8           |
| Amikacin                           | ≤ 8         |
| Gentamicin                         | ≤ 1         |
| Tigecycline                        | 2           |
| Nalidixic acid                     | ≥ 64        |
| Levofloxacin                       | 2           |
| Fosfomycin                         | ≥ 64        |
| Trimethoprim/sulfamethoxazole      | ≤ 2         |

*MIC minimum inhibitory concentration*
Discussion and conclusions

The novelty of *E. asburiae* in this case is the demonstration of colistin resistance with *mcr-9* on the chromosome. Most *mcr-9* genes are located on plasmids; a previous report stated that only 7.8% (6/78) of identified *mcr-9* genes are located on chromosomes of Enterobacteriaceae strains from human, animal, food, and the environment [6]. The *mcr* gene is believed to be mobile in various genetic elements and can be integrated into chromosomes, making colistin resistance prevalent in a large number of Enterobacteriaceae [1]. To our knowledge, this is the first report of colistin resistance in strains expressing chromosomal *mcr-9* and *blaIMP-60*. Reports of *mcr-9* on human chromosomes are rare; we summarize three cases in Additional file 3: Table S1 [10–12]. Whether there are differences in characteristics, such as susceptibility to colistin, between Enterobacteriaceae carrying *mcr-9* on plasmids and on their chromosomes is unclear.

Surprisingly, the patient in this case was infected with an *E. asburiae* strain resistant to colistin even though she had not been exposed to colistin. In our opinion, *mcr-9* and colistin resistance have not been adequately investigated. In the current case, BMD showed colistin resistance, and multiple micro-colonies were also present within the zone of inhibition circle in both E test and disk diffusion method. Napier et al. reported colistin susceptibility of *E. cloacae* determined using the E test; they showed that small colonies were found in the zone of inhibition [13], as in this case, which they described as “heteroresistant”. Although colistin susceptibility testing for CPE is difficult, BMD is the most reliable test [14, 15] and we judged the strain was resistant to colistin. Strains that are heteroresistant to colistin are considered to become resistant to the drug after treatment with colistin and regain sensitivity in the absence of colistin exposure. Furthermore, Kieffer et al. reported that the expression of cloned *mcr-9* in Enterobacteriaceae does not significantly affect colistin susceptibility and that exposure of bacteria to colistin, in addition to the introduction of *mcr-9*, may induce *mcr-9* expression and lead to colistin resistance [16]. Three previous reports showed that Enterobacteriaceae isolated from humans with *mcr-9* on the chromosome were colistin-sensitive (Additional file 3: Table S1) [10–12], whereas *E. asburiae* in the current case was resistant to colistin despite the lack of exposure to the drug. Further studies are needed to determine whether the presence of *mcr-9* on the chromosome influences clinical colistin susceptibility. Moreover, it is possible that *mcr-9* and *blaIMP-60* gene were transferred from the *B. thetaiotaomicron* detected from the patient, although it was susceptible to carbapenem and ampicillin/sulbactam. We could not conduct a further investigation because we first initiated treatment with piperacillin/tazobactam and after the empyema recurred, microbiology testing results could not detect *B. thetaiotaomicron*. This is a limitation of this study.

In conclusion, we identified a colistin-resistant strain of *E. asburiae* that simultaneously possesses *mcr-9* and *blaIMP-60* genes on its chromosome. The presence of *mcr-9* on the chromosome may be associated with colistin resistance.

**Abbreviations**
CPE: Carbapenemase-producing Enterobacteriaceae; *mcr*: Mobile colistin-resistance; BMD: Broth microdilution.

**Supplementary information**
The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07730-7.

**Additional file 1:** Supplementary Figure 1. Image of Enterobacter asburiae isolate colR/S plated on Mueller-Hinton agar with a colistin E test strip (left) and the disc diffusion method (right). Resistant colonies were present within the zone of clearing.
Acknowledgements

None.

Author contributions

Conceptualization of the work: NO; design of the work: KH; clinical management of the patient and data curation: YM and NI; funding acquisition: NI and TS; investigation, analysis, and interpretation of microbiological data: MN, KM and TM; visualization of the genetical data analysis: MU; writing original draft: YM, NI, MU; substantial revision of the manuscript: TM, KH and NO; All authors have read and approved the manuscript.

Authors information

Yusuke Miyazato is a clinical fellow in the Disease Control and Prevention Center at the National Center for Global Health and Medicine. His primary research interests are sexually transmitted diseases and clinical infectious diseases.

Author details

1 Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. 2 Laboratory of Food Microbiology and Food Safety, Department of Health and Environmental Sciences, School of Veterinary Medicine, Rakuno Gakuen University, Hokkaido, Japan. 3 Laboratory of Veterinary Hygiene, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan. 4 Graduate School of Infectious Diseases, Hokkaido University, Sapporo, Japan. 5 Pathogenic Microbe Laboratory, National Center for Global Health and Medicine, Tokyo, Japan. 6 Department of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan.

References

1. Hughes S, Gilchrist M, Heard K, Hamilton R, Sneddon J, et al. Treating infections caused by carbapenemase-producing Enterobacteriales (CPE): a pragmatic approach to antimicrobial stewardship on behalf of the UKCPA Pharmacy Infection Network (PIN). JAC Antimicrob Resist. 2020;2:dlaa075. https://doi.org/10.1093/jac/dlaa075.

2. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161–8. https://doi.org/10.1016/S1473-3099(15)00424-7.

3. Sun J, Zhang H, Liu YH, Feng Y. Towards understanding MCR-like colistin resistance. Trends Microbiol. 2018;26:794–808. https://doi.org/10.1016/j.tim.2018.02.006.

4. Hussein NH, Al-Kadmy IMS, Taha BM, Hussein JD. Mobilized colistin resistance (mcr) genes from 1 to 10: a comprehensive review. Mol Biol Rep. 2021;48:2897–907. https://doi.org/10.1007/s11033-021-06307-y.

5. Kim JS, Yu JK, Jeon SJ, Park SH, Han S, Park SH, et al. Distribution of mcr genes among carbapenem-resistant Enterobacteriales clinical isolates: high prevalence of mcr-positive Enterobacter cloacae complex in Seoul, Republic of Korea. Int J Antimicrob Agents. 2021;58:106418. https://doi.org/10.1016/j.ijantimicag.2021.106418.

6. Li Y, Dai X, Zeng J, Gao Y, Zhang Z, Zhang L. Characterization of the global distribution and diversified plasmid reservoirs of the colistin resistance gene mcr-9. Sci Rep. 2020;10:8113. https://doi.org/10.1038/s41598-020-65106-w.

7. Salmela L, Rivals E, LoREDEC: accurate and efficient long read error correction. Bioinformatics. 2014;30:3506–14. https://doi.org/10.1093/bioinformatics/btu538.

8. Kolmogorov M, Yuan J, Lin Y, Pezner PA. Assembly of long, error-prone reads using repeat graphs. Nat Biotechnol. 2019;37:540–6. https://doi.org/10.1038/s41587-019-0072-8.

9. Walker BJ, Abeel T, Shea T, Priest M, Abouelliel A, Sakhikumar S, et al. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. PLoS ONE. 2014;9:e112963. https://doi.org/10.1371/journal.pone.0112963.

10. Kanianzadeh P, Osaka S, Watanabe S, Iwata S, Kuwahara-Arai K, Shimojima M, et al. Emergence of carbapenem-resistant and colistin-susceptible Enterobacter cloacae complex co-harboring blalamp/M and mcr-9 in Japan. BMC Infect Dis. 2020;20:282. https://doi.org/10.1186/s12879-020-05021-7.

11. Ribeiro TG, Izdebski R, Urbanowicz P, Carmeli Y, Gniadkowski M, Peere L. Citrobacter telavivum sp. nov. with chromosomal mcr-9 from hospitalized patients. Eur J Clin Microbiol Infect Dis. 2021;40:123–31. https://doi.org/10.1007/s10096-020-04003-6.

12. Marchetti VM, Bitar I, Sarti M, Fogato E, Scaltriti E, Bracchi C, et al. Genomic characterization of VIM and MCR co-producers: the first two clinical cases, in Italy. Diagnostics (Basel). 2021. https://doi.org/10.3390/diagnostics11010079.

13. Napier BA, Band V, Burd EM, Weiss DS. Colistin heteroresistance in Citrobacter freundii. J Clin Microbiol. 2020;58:e00797-20. https://doi.org/10.1128/JCM.00797-20.

14. Pfennigwerth N, Kaminski A, Korte-Berwanger M, Pfeifer Y, Simon M, Werner G, et al. Evaluation of six commercial products for colistin susceptibility testing in Enterobacteriales. Clin Microbiol Infect. 2019;25:1385–9. https://doi.org/10.1016/j.cmi.2019.03.017.

15. Matuschek E, Ahman J, Webster C, Kahlmeter G. Antimicrobial susceptibility testing of colistin—evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. Clin Microbiol Infect. 2018;24:865–70. https://doi.org/10.1016/j.cmi.2017.11.020.

16. Kieffer N, Royer G, Decousser JW, Bourrel AS, Palmieri M, Ortiz de La Rosa JM, et al. mcr-9, an inducible gene encoding an acquired phosphoethanolamine transferase in Escherichia coli, and its origin. Antimicrob Agents Chemother. 2019;63:e00965-e1019. https://doi.org/10.1128/AAC.00965-19.